Determination of clinical and metabolic features in pre- and postmenopausal women with type 2 diabetes mellitus and osteoarthrosis against the background of visfatin metabolism disorders

Abstract

Objective — to determine the clinical and metabolic features of pre‑ and postmenopausal women with type 2 diabetes mellitus (DM2) and osteoarthritis (OA) against the background of impaired metabolism of visfatin (VF).
 Materials and methods. 120 pre‑ and postmenopausal women were selected for the study and divided into 3 groups: group 1 included women with isolated DM2; group 2 — women with isolated OA; group 3 — women with DM2, combined with OA. The control group consisted of 16 healthy women. Investigations included anthropometric measurements, assessment of the indices of lipid and carbohydrate exchange and clinical manifestations of premenopause and postmenopause. Determination of the serum VF levels of patients was performed by enzyme‑linked immunosorbent assay on the analyzer «Labline‑90» (Austria).
 Results. Investigation of the specific features of the DM2 and OA course in premenopausal women demonstrated violations of carbohydrate and lipid metabolism, defined by the significant (р < 0.001) increase in VF levels up to (3.9 ± 1.2 ng/ml) and (4.2 ± 1.1 ng/ml), respectively. The highest VF level was recorded in the group of comorbid DM2 and OA (5.5 ± 1.0 ng/ml) compared with the levels of relatively healthy women of the same age group (1.8 ± 0.5 ng/ml). Moreover, the high indices of body mass index, waist and hip circumference, systolic and diastolic pressure, as well as of the menopausal index were established at DM2 and OA vs control group.
 Conclusions. Clinical and metabolic disorders have been identified in pre‑ and postmenopausal women against the background of OA and DM2 based on the significant (р < 0.001) increase in visfatin levels, especially in case of comorbid OA and DM2, as compared to the control group of age‑matched practically healthy women.